Background: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozolepalbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC.
Background: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozolepalbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC.
Patients and methods: NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna V R -defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m 2 , epirubicin 100 mg/m 2 , cyclophosphamide 500 mg/m 2 )Â3 21-day courses followed by docetaxel 100 mg/m 2 Â3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety.
Results: Overall, 106 patients were randomised [median Prosigna
V R ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7. 7% (95% CI 0.4-14.9)] and chemotherapy [15. 7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm).
Conclusion: LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna
V R -defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less favourable safety profile. LETPAL combination might represent an alternative to chemotherapy in early high-risk LBC.
Introduction
Estrogen receptor (ER)-positive, HER2-negative breast cancer (luminal breast cancer, LBC) accounts for $65%-70% of all invasive breast carcinomas [1] . In early stages, adjuvant endocrine therapy (ET) has consistently shown clinically significant and long-term benefits, in terms of invasive disease-free survival and overall survival [2, 3] , although compliance to treatment may be limited by side-effects [4] . It has been recently demonstrated that first generation genomic signatures such as Mammaprint/ Blueprint V R may help sorting high-and low-risk LBC [5, 6] . Data from second-generation transcriptomic signatures such as PAM50 (Prosigna V R ) or EPclin V R , which include clinical parameters, suggest that they could even more accurately select patients who could avoid chemotherapy [7, 8] .
Meanwhile, a new class of agents, cyclin-dependent kinase 4/6 inhibitors (CDKi), has been evaluated in the advanced setting. Palbociclib is a first-in-class oral CDKi that, in combination with ET, provides a significant increase in objective response rates and in long-term progression-free survival in patients with advanced breast cancer, and with excellent tolerability [9] [10] [11] [12] .
So far, no prospective study has compared a CDKi-ET combination with cytotoxic chemotherapy. The residual cancer burden (RCB), a standardised measure of pathological response, has recently been shown to accurately correlate pathological response and prognosis in patients with LBC treated with neoadjuvant cytotoxic chemotherapy (NACT) [13] . To test the hypothesis that a palbociclib-ET combination could generate results similar to conventional NACT, we proposed a proof-of-concept study evaluating the letrozole-palbociclib combination as neoadjuvant therapy and NACT in LBC patients selected with a secondgeneration transcriptomic signature.
Patients and methods

Study design, patients and randomisation
In this prospective, international, multicentre, randomised, parallel, non-comparative phase II clinical trial, we recruited patients with HER2-negative stage II-IIIA invasive breast carcinoma, not candidate for BCS, from 22 centres across France and Belgium. This academic study was sponsored by UNICANCER, conducted within the French Breast Cancer Intergroup (UCBG), and registered at clinicaltrials.gov (NCT02400567) as the NeoPAL study (supplementary Figure S1 , available at Annals of Oncology online). Eligible patients were randomised in a 1 : 1 ratio to either arm A (letrozole þpalbociclib) or arm B (standard chemotherapy). Detailed eligibility criteria and patients randomisation are described in the supplementary Methods, available at Annals of Oncology online. The study, which received the approval of the regulatory authorities on 12 December 2014, was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. We obtained two written informed consents from all randomised patients (before enrolment and before randomisation after Prosigna V R test results and axillary lymph node characterisation). The study obtained full approval by a national French Ethic Committee (CPP Ile de France III, Paris, France) and by local IRB (UCL Saint-Luc) in Belgium.
Procedures
A representative sample of core needle biopsies of the primary tumour was sent to Institut Curie's Tumour Biology Department (Paris, France) for central pathology review, RNA preparation, and Prosigna V R testing. Details of testing procedures are described in the supplementary Methods, available at Annals of Oncology online.
Patients randomised in arm A were to receive 28-day cycles of continuous daily letrozole, 2.5 mg/day, and palbociclib, 125 mg/day, according to a 3 weeks on/1 week off schedule, for a total duration of 19 weeks. Breast surgery was carried out 24 h after the last palbociclib and letrozole doses. Patients randomised in the standard chemotherapy arm were to receive six conventional third-generation 21-day cycles of sequential chemotherapy: FEC100 during cycles 1-3, and docetaxel 100 mg/sqm (D100) during cycles 4-6. Patients were clinically evaluated at day 1 of each cycle in each arm. Imaging studies [mammogram, ultrasound (US) tumour evaluation] were carried out after cycle 2 (arm A) and 3 (arm B), i.e. after the same duration of treatment (8 weeks), and immediately before surgery.
Breast surgery was carried out at day 1 of week 20, i.e. at day 21 of the fifth cycle of LETPAL, and 4 weeks after the last chemotherapy infusion. Preoperative radiation therapy was not permitted per protocol. Lymph node surgery was carried out at the same time as breast surgery, according to local procedures. Sentinel lymph node (SLN) surgery was allowed only after completion of the neoadjuvant therapy. Patients with pN0, pN0iþ, or pN1mi SLN were classified pN0 for RCB calculation. Patients who did not achieve RCB 0-I in LETPAL arm were recommended to receive adjuvant chemotherapy.
RCB was locally assessed for evaluation of the primary end point according to the MD Anderson Cancer Center recommendations for which pathologists of participating centres were specifically trained. After local evaluation, tumour blocks were sent to Institut Curie Tumour Biology Department for a blinded centralised review of RCB and central assessment of secondary biological end points.
Outcomes
The primary end point was RCB. Secondary end points included locally assessed clinical response (clinical examination and US measurements), central RCB evaluation, pathological complete response (pCR) rates, Ki67 decrease, PEPI scores for breast cancer-specific survival (BCSS), and relapse-free survival (RFS) as computed in Ellis et al. [14] , and evaluation of the predictive value of the ROR score.
We evaluated safety and graded side-effects according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0 (details in the supplementary Appendix, available at Annals of Oncology online).
Statistical analysis
This phase II trial was based on a Fleming's two-step statistical design. The main objective was to evaluate the ability of each treatment strategy to provide RCB 0-I pathological tumour response at surgery (local assessment) in luminal A Nþ and luminal B patients. Based on the RCB 0-I results with standard chemotherapy [13] , the null hypothesis (p0) was a RCB 0-I observed in 20% of cases (p0 ¼ 0.20), while the alternative hypothesis was p1 ¼ 0.40. Considering a type I error of 0.045 and a type II error of 0.042 (power ¼95.8%), the required number of patients was 60 assessable patients per arm at final analysis. Assuming a 10% drop-off, another 10% of PAM50 assessable patients classified as non-luminal, and taking into account potential technical failures, 186 patients were to be screened.
In order to minimise risks, we planned an interim analysis by an independent data monitoring committee when 30 patients were available for local RCB evaluation in the LETPAL arm, though without stopping recruitment. The decision rule is described in the supplementary Methods, available at Annals of Oncology online.
Principal analyses give the proportion of RCB 0-I patients in each group, with their 95% confidence intervals. The main objective was evaluated on the intent-to-treat population of patients. Secondary end points were assessed using classical descriptive statistical methods and results are given with their 95% confidence intervals. Safety was analysed on the safety population defined as all patients who received at least one treatment dose after randomisation, regardless of their eligibility for the study. All analyses were carried out using R software (version 3.2.2) (http:// cran.r-project.org).
Results
Between 14 February 2015 and 15 November 2016, 186 patients were screened in 22 centres in France and Belgium. Of those, 59 were finally not eligible due mostly to undetermined axillary lymph node status (n ¼ 16) or Prosigna V R non-luminal status (n ¼ 15) (Figure 1) . Of 125 included patients, 19 had nodenegative Luminal A breast cancer who were proposed to enter an open parallel letrozole-palbociclib cohort. When the interim analysis mandated the accrual to be stopped early, a total of 106 patients (53 in each arm, Figure 1 ) had been randomised (intentto-treat and safety population).
Baseline characteristics of the randomised population are shown in Table 1 . Median age of the whole population was 63 years (48-80). Tumour characteristics were well balanced between the two arms, with predominantly high-risk, luminal B features. By US measure, the median tumour size was 27 mm (8-100) in both arms. The median ROR score value of the 106 randomised patients was 71 (22-93), thus leading $85% of tumours to be classified as 'high-risk' according to the Prosigna V R test. Per protocol, an interim analysis was conducted when 30 patients had undergone surgery in the LETPAL arm. At the same time, 30 patients had also undergone surgery in the chemotherapy arm. Overall, only one patient in the LETPAL arm had a locally assessed RCB 0-I response (3.3%, 95% CI 0% to 9.8%) ( Table 2) . As the predefined threshold of six patients with RCB 0-I in the LETPAL arm was not crossed (see supplementary Methods, available at Annals of Oncology online), accrual was stopped. Only three patients achieved RCB 0-I in the chemotherapy arm (10%, 95% CI 0% to 20.7%). 
Primary end point
At the time accrual was stopped, 106 patients had been included and went on the planned therapy. At final analysis ( 
Secondary end points
Only two patients in arm A, and three in arm B, had a complete pathological response (RCB 0; see supplementary Table S2 , available at Annals of Oncology online). The baseline ROR score did not correlate with RCB in any arm (all exploratory P values for contingency tables were >0.6), nor was there a correlation when treating ROR and RCB as continuous variables (Spearman rank correlation q ¼À0.107; P ¼ 0.284) (supplementary Table S3 , available at Annals of Oncology online). Baseline Ki67 values were high as shown in Tables 1 and 3 . The geometric mean of Ki67 expression was sharply decreased with both therapies, with scores of 1.17% and 3.7% at surgery, respectively. For both BCSS and RFS PEPI scores, the letrozole-palbociclib combination carried out at least as well as chemotherapy (Table 3) . Respective results for luminal A and B tumours are shown in supplementary Table  S5 , available at Annals of Oncology online. Clinical response and BCS rates were almost identical in both arms (supplementary Table S4 , available at Annals of Oncology online). With a median follow-up of 9.9 months (3-23), only four invasive disease-related events were recorded. They included one second cancer, two metastatic events (one in arm A with bone metastases 17 months after inclusion, one in arm B with CNS metastases 5.7 months after inclusion) and one death in a patient who committed suicide before starting treatment. Of note, only 16 out of the 48 patients (33.3%) who did not achieve RCB 0-I in the LETPAL arm accepted to receive adjuvant chemotherapy.
In the LETPAL arm, the most common adverse events were neutropenia, leukopenia, fatigue and hot flushes (supplementary Table S6 , available at Annals of Oncology online). All patients had at least one adverse event. No cases of neutropenic infection or fever were observed. Most of other events were of grade 1. Out of 21 patients who experienced grade 3-4 adverse events in the LETPAL arm, 19 had haematological side-effects with no clinical consequence. One patient had a non-treatment related grade 3 hypertension episode, and another a transient c-glutamyl transferase elevation. Adverse events were almost twice as frequent in the chemotherapy arm. Nine episodes (occurring in 17% of patients) of grade 3-4 febrile neutropenia/neutropenic fever were recorded. Grade 3 lymphopenia was also commonly observed. No treatment-related death was recorded. As defined by US examination and fine needle aspiration or biopsy. Serious adverse events and adverse events leading to dose reduction or discontinuation are summarised in Table 4 . Sixteen adverse events led to a dose reduction of palbociclib and only two serious adverse events occurred, leading to palbociclib discontinuation. Of note, 17 serious adverse events were recorded in the docetaxel part of the chemotherapy schedule, and included 12 episodes of febrile neutropenia, 2 episodes of colitis, 1 pyelonephritis, 1 bilateral pneumonia and 1 transient ischemic attack. Chemotherapy dose reduction and/or interruption were necessary in 20 patients. Treatment with docetaxel was discontinued in seven patients.
Discussion
The NeoPAL study is the first trial to evaluate the CDKi-ET combination versus cytotoxic chemotherapy in the neoadjuvant setting in patients with high-risk LBC. NeoPAL is also the first study to demonstrate feasibility of real-time selection for a neoadjuvant study using the PAM50 intrinsic subtypes. In this exploratory, parallel, non-comparative phase II study, the letrozole-palbociclib combination did not reach the primary end point of 20% RCB 0-I after 19 weeks of treatment (7.7%; 95% CI 0.4-14.9), and generated pCR in only two patients (3.8%). Duration of 16-18 weeks of neoadjuvant ET is a commonly accepted schedule and has been validated in randomised studies [15, 16] . Noteworthy, thirdgeneration NACT with the same treatment duration, an accepted option in patients with LBC not candidate for upfront BCS, also carried out very poorly in this study with 15.7% RBC 0-I (95% CI 5.7-25.7) and no more than three patients achieving a pCR (5.9%). It is striking that these poor results with chemotherapy were obtained in a highly selected population, where high risk was defined by a second-generation transcriptomic signature, underlining the need for alternative therapies in this population. It is admitted that pCR has a much less powerful prognostic value for LBC than for other breast cancer subtypes, which contrasts with the lower pathological response rates observed in this subtype [17] . The recent update of the ACOSOG Z1031 trial has strongly suggested that endocrine-resistant tumours also achieved very low pCR rates with chemotherapy, while those achieving a PEPI 0 response (and not receiving chemotherapy) had an excellent longterm prognosis [18] .
Secondary end points analyses showed promising results. The LETPAL combination allowed a profound decrease in Ki67 levels, at least equivalent to that obtained by chemotherapy. It translated into very encouraging BCSS and RFS PEPI scores with a potential long-term beneficial effect [14] . However, it has never been validated in prospective trials. Analyses of clinical secondary end points were also very encouraging. Clinical response and BCS rates were strikingly similar in both arms. These results confirm the impressive efficacy of LETPAL and of similar CDKi-ET combinations in the advanced, yet aromatase inhibitor-sensitive breast cancer setting [9, 10, 19, 20] , and are in the high range of previously reported results from neoadjuvant randomised studies comparing ET and chemotherapies [21] . Adverse events, in line with expectations, clearly favour the LETPAL combination. We are fully aware of the limitations of this trial. We recruited mostly luminal B breast cancer patients, and the very limited number of luminal A patients hinders any conclusion pertaining to specific intrinsic subtypes. Furthermore, the primary end point (RCB) might not be the most suitable for the evaluation of neoadjuvant ET. However, as the standard arm for high-risk LBC required chemotherapy, it was necessary to use RCB as the primary end point for the experimental arm as well. Our hypotheses regarding the primary end point in this proof-of-concept trial were clearly too optimistic. This might likely be attributable to the cytostatic mode of action of endocrine therapies and CDK4/6 inhibitors. The treatment duration with the letrozole-palbociclib combination is also questionable. It has long been shown that extending duration of neoadjuvant ET improves clinical response and breast conservation [15] , though with no demonstration of improvement in pathological response. We also had to control for treatment duration in both arms. We are aware that, as planned per protocol, additional follow-up is needed to further establish the long-term impact of the LETPAL combination.
In summary, the results of this hypothesis-generating trial were negative on the primary end point with a low rate of pathological responses in both arms. However, they showed similar biological and clinical effects between a CDKi-ET combination and chemotherapy for the neoadjuvant treatment of high-risk LBC patients. It is our belief that the favourable benefit-risk profile of the letrozole-palbociclib combination observed in this early, pilot trial will help define CDKi-ET combinations as candidates for chemotherapy replacement in high-risk LBC. Technologies for providing the Prosigna V R tests.
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